Q4 2022 Results

Company overview Financial review 2023 priorities Appendix INNOVATION KisqaliⓇ - NATALEE study continues following first interim analysis; final readout expected H2 2023 NATALEE: HR+/HER2- pre- and post-menopausal, early breast cancer Stage II & III | N=5000 R 1:1 3 weeks on/1 week off 36 months KISQALIⓇ Endocrine therapy (NSAI + goserelin³) Endocrine therapy (NSAI + goserelin³) 60 months 60 months Patient population: 218K patients with early breast cancer in US + EU1 NATALEE differentiation Broad population including anatomical Stage II and III² Longer treatment duration of 3 vs. 2 years (monarchE) Lower dose (400mg/day) to potentially improve tolerability and adherence without compromising efficacy Study status Final analysis planned at 500 iDFS events, expected H2 2023 1st interim analysis at 70% of events (completed, study continues) 2nd interim analysis at 85% of events NSAI - non-steroidal aromatase inhibitor. 1. eBC Patient - Adjuvant Breast Cancer Opportunity Assessment June 2020. 2. Based on AJCC prognostic staging. 60% Stage III and 40% Stage II patients in study. Stage II vs. Stage III is a stratification factor. The trial did not require Ki-67% or other CDx for patient identification or stratification, but Ki-67% is part of the statistical analysis plan. 3. In pre-menopausal women and in men. 13 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation